29 January 2025
29 January 2025
The approval solidifies Novo Nordisk’s Ozempic as the most broadly indicated GLP-1RA in the US.
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.
ITM Radiopharma has announced that its Phase III trial examining its gastroenteropancreatic tumour treatment, ITM-11, met its primary endpoint.
Arena International’s OCT West Coast 2025 conference will discuss patient centricity, diversity, and regulatory shifts.
The decision is based on preliminary clinical evidence from Phase II trials DAWN and SKYLINE.
The patent will be effective until February 2038.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
